ERBB2 and breast carcinoma: Since the adoption of this agent into the routine management of early stage HER2 positive breast cancer, adding trastuzumab to chemotherapy has led to a 37% relative improvement in overall survival and relevant patients can now expect a 10-year survival rate of up to 85%, as compared to 75% prior to trastuzumab use [5].